MSI2 and colorectal carcinoma: The survival analysis showed that there was no significant difference in prognosis between CRC patients with high and low MSI2 expression in the CRC TCGA database (p = 0.093), GSE17536 (p = 0.71) and GSE14333 (p = 0.54) datasets (Fig. 8A).